Skip to main content

Table 3 Correlation between clinicopathological factors and the LOH status at the 16q22 minimal locus

From: Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer

Factor

Loss of heterozygosity

Retention of heterozygosity

Total

P

Total

22 (51.2%)

21 (48.8%)

43 (100%)

 

Age (year)

    

≤ 50

7 (43.8%)

9 (56.2%)

16

NS

> 50

15 (55.6%)

12 (44.4%)

27

 

Tumor size

    

< 2.0

6 (46.2%)

7 (53.8%)

13

NS

≥ 2.0

16 (55.2%)

13 (44.8%)

29

 

Not measurable

0

1

1

 

Lymph node

    

Negative

9 (37.5%)

15 (62.5%)

24

0.084

Positive

11 (64.7%)

6 (45.3%)

17

 

Unknown

2

0

2

 

Histological grade

    

1/2

6 (60.0%)

4 (40.0%)

10

NS

3

14 (50.0%)

14 (50.0%)

28

 

Unknown

2

3

5

 

Estrogen receptor-α

    

Negative

4 (40.0%)

6 (60.0%)

10

NS

Positive

17 (54.8%)

14 (45.2%)

31

 

Unknown

1

1

2

 

Progesterone receptor

    

Negative

2 (18.2%)

9 (81.8%)

11

0.013*

Positive

16 (61.5%)

10 (38.5%)

26

 

Unknown

4

2

6

 

HER2

    

Negative

18 (60.0%)

12 (40.0%)

30

 

Positive

2 (20.0%)

8 (80.0%)

10

0.024*

Unknown

2

1

3

 
  1. Estrogen receptor-α, progesterone receptor, and human epidermal growth factor (HER) 2 were determined histochemically.
  2. *P < 0.05.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us